Literature DB >> 17082566

Nucleic acid-sensing TLRs as modifiers of autoimmunity.

Jonathan A Deane1, Silvia Bolland.   

Abstract

The immune system requires precise regulation of activating and inhibitory signals so that it can mount effective responses against pathogens while ensuring tolerance to self-components. Some of the most potent activation signals are triggered by innate immune molecules, particularly those in the TLR family. Recent studies have shown that engagement of TLRs plays a significant role in both innate and adaptive immunity. This review focuses on the ways that TLR function might contribute to the etiology of lupus-like syndromes in the context of an autoimmune-prone environment. By considering the sources, localization, and expression of both nucleic acids and the molecules that bind them, we discuss several ways that innate immunity can play a role in the development of systemic autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082566     DOI: 10.4049/jimmunol.177.10.6573

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Microparticles as autoadjuvants in the pathogenesis of SLE.

Authors:  David S Pisetsky; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

Review 2.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

Review 3.  Dendritic cells and cytokines in human inflammatory and autoimmune diseases.

Authors:  Patrick Blanco; A Karolina Palucka; Virginia Pascual; Jacques Banchereau
Journal:  Cytokine Growth Factor Rev       Date:  2008-02       Impact factor: 7.638

Review 4.  Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity.

Authors:  Divaker Choubey; Xin Duan; Eric Dickerson; Larissa Ponomareva; Ravichandran Panchanathan; Hui Shen; Ratika Srivastava
Journal:  J Interferon Cytokine Res       Date:  2010-06       Impact factor: 2.607

5.  Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation.

Authors:  Jonathan A Deane; Prapaporn Pisitkun; Rebecca S Barrett; Lionel Feigenbaum; Terrence Town; Jerrold M Ward; Richard A Flavell; Silvia Bolland
Journal:  Immunity       Date:  2007-11-08       Impact factor: 31.745

Review 6.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

7.  Treatment with a toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice.

Authors:  Kareem L Graham; Lowen Y Lee; John P Higgins; Lawrence Steinman; Paul J Utz; Peggy P Ho
Journal:  Autoimmunity       Date:  2010-03       Impact factor: 2.815

8.  Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

Authors:  James O McNamara; Despina Kolonias; Fernando Pastor; Robert S Mittler; Lieping Chen; Paloma H Giangrande; Bruce Sullenger; Eli Gilboa
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 9.  Toll-Like Receptors in the Pathogenesis of Autoimmune Diseases.

Authors:  Akbar Mohammad Hosseini; Jafar Majidi; Behzad Baradaran; Mehdi Yousefi
Journal:  Adv Pharm Bull       Date:  2015-12-31

10.  Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense.

Authors:  Luis B Barreiro; Meriem Ben-Ali; Hélène Quach; Guillaume Laval; Etienne Patin; Joseph K Pickrell; Christiane Bouchier; Magali Tichit; Olivier Neyrolles; Brigitte Gicquel; Judith R Kidd; Kenneth K Kidd; Alexandre Alcaïs; Josiane Ragimbeau; Sandra Pellegrini; Laurent Abel; Jean-Laurent Casanova; Lluís Quintana-Murci
Journal:  PLoS Genet       Date:  2009-07-17       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.